Product image of Mosmass (Alendronate Sodium Trihydrate) supplied by GNH India

Mosmass

Active Ingredient:
Alendronate Sodium Trihydrate
Origin:
EU

Mosmass (Alendronate Sodium Trihydrate)

Alendronate sodium, the active ingredient in Mosmass, is a bisphosphonate presented as an oral tablet for oral use. It treats osteoporosis and related bone disorders in adult patients, helping to reduce fracture risk by inhibiting bone resorption. By binding to bone mineral surfaces, it selectively targets osteoclast activity, leading to decreased bone turnover.

GNH India supplies Mosmass as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards.

Manufacturer / TM Owner

Rafarm Sa.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mosmass (alendronate sodium) is indicated for conditions involving increased bone turnover within the skeletal system.

  • Osteoporosis: reduces risk of vertebral and hip fractures by inhibiting bone resorption.
  • Paget's disease of bone: normalizes abnormal bone remodeling and alleviates bone pain.
  • Glucocorticoid‑induced osteoporosis: prevents bone loss associated with long‑term corticosteroid therapy.

How It Works

  • Alendronate sodium is a nitrogen‑containing bisphosphonate that binds avidly to hydroxyapatite crystals on bone surfaces. When osteoclasts resorb bone, the drug is internalized and inhibits farnesyl pyrophosphate synthase within the mevalonate pathway, disrupting prenylation of small GTP‑binding proteins. This impairs osteoclast function and promotes apoptosis, thereby decreasing bone resorption and turnover.

Side Effects

Alendronate sodium may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Upper gastrointestinal irritation: dyspepsia, abdominal pain, or nausea.
  • Esophageal discomfort: heartburn or reflux symptoms.
  • Musculoskeletal pain: transient bone, joint, or muscle aches.
  • Headache: mild to moderate intensity.
  • Flu‑like symptoms: transient fever or chills.

Serious or Rare Side Effects

  • Osteonecrosis of the jaw: exposed bone in the oral cavity.
  • Atypical femoral fractures: low‑energy fractures of the subtrochanteric region.
  • Severe esophageal ulceration or perforation.
  • Acute renal impairment: sudden decrease in kidney function.
  • Hypocalcemia: low blood calcium levels requiring monitoring.

Precautions & Warnings

When prescribing Mosmass, clinicians should consider several precautionary measures to ensure safe use.

  • Assess renal function: avoid use in patients with severe renal impairment.
  • Verify calcium and vitamin D status: correct deficiencies before initiating therapy.
  • Review gastrointestinal history: contraindicated in patients with esophageal disorders.
  • Advise upright posture: take the tablet with a full glass of water and remain upright for at least 30 minutes.
  • Monitor for atypical fractures: evaluate persistent thigh or groin pain.
  • Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Avoid Interactions

Alendronate sodium can interact with other medicines, affecting its absorption or increasing toxicity.

Major Interactions (Avoid)

  • Calcium supplements or antacids containing calcium, magnesium, aluminum, or iron: markedly reduce alendronate absorption.
  • Concomitant use of other bisphosphonates: increased risk of cumulative bone toxicity.
  • Systemic corticosteroids: may exacerbate risk of osteonecrosis of the jaw.

Moderate Interactions (Monitor Closely)

  • Proton pump inhibitors: may alter gastric pH and affect drug bioavailability.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase risk of gastrointestinal irritation.
  • Diuretics (loop or thiazide): may predispose to hypocalcemia; monitor serum calcium levels.

Frequently Asked Questions

Mosmass contains alendronate sodium, a bisphosphonate indicated for the treatment of osteoporosis, Paget's disease of bone, and glucocorticoid‑induced osteoporosis. It works by reducing bone resorption, thereby helping to lower the risk of fractures in patients with these bone‑loss conditions.

Alendronate sodium binds to hydroxyapatite on bone surfaces and is taken up by osteoclasts during bone resorption. Inside the cell it inhibits the enzyme farnesyl pyrophosphate synthase, disrupting the mevalonate pathway and preventing prenylation of proteins essential for osteoclast function, leading to reduced bone breakdown.

The dosage of Mosmass is determined individually by the prescribing healthcare professional based on the patient’s condition, renal function, and other clinical factors. Patients should follow the prescriber’s instructions and not alter the dose without medical guidance.

Alendronate sodium is generally not recommended for use during pregnancy or while breastfeeding because safety data are limited. Women who are pregnant, planning to become pregnant, or nursing should discuss alternative treatment options with their healthcare provider.

To order Mosmass, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mosmass (alendronate) is a first‑line oral bisphosphonate, offering a convenient once‑weekly or once‑monthly regimen compared with daily calcium‑based supplements. Compared with intravenous bisphosphonates, it avoids infusion‑related reactions but requires strict administration instructions to minimise gastrointestinal irritation.

Mosmass should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture. Keep the product out of reach of children and avoid exposure to direct sunlight or high humidity.

Mosmass is taken orally with a full glass of plain water on an empty stomach, preferably first thing in the morning. The patient should remain upright for at least 30 minutes and avoid eating, drinking, or taking other medications during this period to ensure optimal absorption.

Serious adverse events associated with Mosmass include osteonecrosis of the jaw, atypical femoral fractures, severe esophageal ulceration or perforation, acute renal impairment, and significant hypocalcemia. Patients should report persistent jaw pain, unexplained thigh or groin pain, or any signs of gastrointestinal bleeding promptly.

Mosmass is contraindicated in patients with known hypersensitivity to alendronate or other bisphosphonates, those with esophageal abnormalities that delay emptying, severe renal impairment (creatinine clearance <30 mL/min), and individuals unable to follow the required upright posture after dosing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Alendronate Sodium Trihydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT